UY27680A1 - Agonistas del receptor b3 - andrenérgicos. - Google Patents

Agonistas del receptor b3 - andrenérgicos.

Info

Publication number
UY27680A1
UY27680A1 UY27680A UY27680A UY27680A1 UY 27680 A1 UY27680 A1 UY 27680A1 UY 27680 A UY27680 A UY 27680A UY 27680 A UY27680 A UY 27680A UY 27680 A1 UY27680 A1 UY 27680A1
Authority
UY
Uruguay
Prior art keywords
andrenérgicos
agonists
adrenergic receptor
receiver agonists
receiver
Prior art date
Application number
UY27680A
Other languages
English (en)
Inventor
Jennifer A Lafontaine
Bradley P Morgan
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of UY27680A1 publication Critical patent/UY27680A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona agonistas del receptor b3-adrenérgico de fórmula estructural (I) , así como formulaciones farmacéuticas de los mismos, métodos para tratar enfermedades, trastornos y/o afecciones mediados por el receptor B3- adrenérgico utilizando dichos compuestos.
UY27680A 2002-02-27 2003-02-25 Agonistas del receptor b3 - andrenérgicos. UY27680A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36025102P 2002-02-27 2002-02-27

Publications (1)

Publication Number Publication Date
UY27680A1 true UY27680A1 (es) 2003-10-31

Family

ID=27766207

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27680A UY27680A1 (es) 2002-02-27 2003-02-25 Agonistas del receptor b3 - andrenérgicos.

Country Status (13)

Country Link
EP (1) EP1485379A1 (es)
JP (1) JP2005518448A (es)
AU (1) AU2003248356A1 (es)
BR (1) BR0308070A (es)
CA (1) CA2476316A1 (es)
DO (1) DOP2003000587A (es)
GT (1) GT200300043A (es)
MX (1) MXPA04007127A (es)
PA (1) PA8567701A1 (es)
PE (1) PE20030943A1 (es)
TW (1) TW200408637A (es)
UY (1) UY27680A1 (es)
WO (1) WO2003072572A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002085297A2 (en) 2001-04-24 2002-10-31 East Carolina University Compositions & formulations with a non-glucocorticoid steroid &/or a ubiquinone & kit for treatment of respiratory & lung disease
US7405207B2 (en) 2002-06-17 2008-07-29 Epigenesis Pharmaceuticals, Inc. Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
GB0324654D0 (en) * 2003-10-22 2003-11-26 Glaxo Group Ltd Medicinal compounds
CA2551167C (en) * 2003-12-23 2011-10-18 Astellas Pharma Inc. Aminoalcohol derivatives
DE102004021779A1 (de) * 2004-04-30 2005-11-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP2400300A1 (en) 2004-08-25 2011-12-28 Takeda Pharmaceutical Company Limited Method of screening preventives/remedies for stress urinary incontinence
PE20091825A1 (es) 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
US20150087832A1 (en) 2011-10-27 2015-03-26 Merck Sharp & Dohme, Corp. Process for making beta 3 agonists and intermediates
ES2584427T3 (es) 2011-10-27 2016-09-27 Merck Sharp & Dohme Corp. Proceso para la preparación de agonistas beta 3 y productos intermedios
ES2746801T3 (es) 2013-03-15 2020-03-06 Merck Sharp & Dohme Proceso de preparación de agonistas beta-3 y productos intermedios
BR112019025636A2 (pt) 2017-06-06 2020-08-25 Urovant Sciences Gmbh método para tratar bexiga hiperativa, método para aumentar relaxamento de músculo liso da bexiga, e composição de dosagem unitária farmacêutica

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO179246C (no) * 1991-11-20 1996-09-04 Sankyo Co Aromatiske amino-alkoholderivater og mellomprodukter til fremstilling derav
DE69527779T2 (de) * 1994-04-08 2003-03-27 Sumitomo Chemical Co., Ltd. Etherverbindungen, ihre verwendung und zwischenprodukte zu ihrer herstellung
WO1996035671A1 (en) * 1995-05-10 1996-11-14 Pfizer Inc. β-ADRENERGIC AGONISTS
GB9812709D0 (en) * 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds
CA2423792A1 (en) * 2000-10-20 2002-04-25 Pfizer Products Inc. Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists

Also Published As

Publication number Publication date
BR0308070A (pt) 2004-12-21
DOP2003000587A (es) 2003-08-30
AU2003248356A1 (en) 2003-09-09
PE20030943A1 (es) 2003-11-08
PA8567701A1 (es) 2003-11-12
WO2003072572A1 (en) 2003-09-04
EP1485379A1 (en) 2004-12-15
JP2005518448A (ja) 2005-06-23
GT200300043A (es) 2003-09-22
CA2476316A1 (en) 2003-09-04
WO2003072572A8 (en) 2004-01-29
TW200408637A (en) 2004-06-01
MXPA04007127A (es) 2005-07-05

Similar Documents

Publication Publication Date Title
UY28766A1 (es) Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico
CR20110077A (es) Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
CY1111977T1 (el) Παραγωγα πιπεριδιν-4-υλ-πυριδαζιν-3-υλαμινης ως ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2
CL2011001263A1 (es) Compuestos derivados de pirimidinonas opcionalmente sustituidas; composicion farmaceutica que los comprende; y su uso como inhibidores de fosfodiesterasa 1 (pde1) para el tratamiento de enfermedades que involucran trastornos de la trayectoria intracelular del receptor de dopamina d1 como parkinson, alzheimer, depresion, enfermedad bipolar, hipertension, glaucoma.
DOP2013000267A (es) Hidroximetil pirrolidinas como agonistas del receptor adrenérgico beta 3
ECSP034809A (es) Ciclobuteno-1,2-dionas 3,4-disustituidas como ligandos del receptor de quimocina cxc
PA8675701A1 (es) Nuevos derivados del fluoreno, composiciones que los contienen y su utilización
ECSP077985A (es) Inhibidores de proteina cinasa derivados de pirrol (2,3-b) piridina
ECSP055535A (es) Derivados de 1-heterociclialquil-3-sulfonilazaindol o azaindol como ligandos de 5-hidroxitriptamina-6
CL2008002793A1 (es) Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
ECSP088511A (es) Agonistas del receptor del neuropeptido-2
ECSP11010885A (es) Heteroarilos sustituidos
AR054786A1 (es) (6-fluor-benzol(1,3) dioxolil)-morfolin-4-il-metanomas, moduladoras del receptor cb1
DE602005021696D1 (de) Indazolcarbonsäureamidverbindungen
PA8663501A1 (es) Derivados de indol, benzotiofeno, benzofurano e indeno cicloalquilcondensados
DOP2006000061A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
ECSP045473A (es) Derivados de 1-(aminoalquil)-3-sulfonilindol y 1-aminoalquil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6
ATE441646T1 (de) 5-ht4-rezeptoragonistenverbindungen
CR10497A (es) Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38
ATE431824T1 (de) Chinolinon-carboxamid-verbindungen
ECSP034811A (es) Derivados heterocicliloxi-, -tioxi - y - aminobenzazole tales como ligandos 5-hidroxitriptamina-6
UY30835A1 (es) 8-alquinilxantinas y derivados
NI200700032A (es) Derivados arilsulfonilestilbeno para tratamiento de insomnio y afecciones relacionadas
CY1113759T1 (el) Ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2
CY1113820T1 (el) Παραγωγα 4-αλκοξυπυριδαζινης ως ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150423